BNP (B-type Natriuretic Peptide) vs BPC-157

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

BNP (B-type Natriuretic Peptide)

BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.

Full details →

BPC-157

Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.

Full details →

Side-by-Side Comparison

Aspect	BNP (B-type Natriuretic Peptide)	BPC-157
Dose Range	25 mcg–100 mcg	250 mcg–500 mcg
Frequency	1x daily	2x daily
Cycle Length	1–4 weeks	4–6 weeks
Route	subcutaneous	subcutaneous
Mechanism	Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress.	BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels.
Typical Dosage	Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure.	Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied.
Administration	Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically.	Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable.
Side Effects	Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients.	Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses.
Best For	Recovery & Healing	Muscle Growth Recovery & Healing